5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. - Wikidata - awgldk - TriplyDB

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

http://www.wikidata.org/entity/Q36715466

about

Elderly patients and inflammatory bowel disease Mesalamine in the treatment and maintenance of remission of ulcerative colitis Therapeutic challenges of managing inflammatory bowel disease in the elderly patient.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Five-aminosalicylic Acid: an update for the reappraisal of an old drug Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Red-Brown Urine Discolouration in Two Patients Taking Mesalamine.Interstitial Nephritis in a Patient with Inflammatory Bowel Disease Mesalazine-induced renal calculi.The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.Second Korean guidelines for the management of ulcerative colitis.Efficacy and safety of drugs for ulcerative colitis.IgA nephropathy in association with Crohn's disease: a case report and brief review of the literature.Drug-induced acute interstitial nephritis.Renal manifestations and complications of inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Topical therapies in inflammatory bowel disease.Extended-release mesalamine granules for ulcerative colitis.Management of the elderly patients with inflammatory bowel disease: practical considerations.Clinical implications of ageing for the management of IBD.Systematic review with meta-analysis: inflammatory bowel disease in the elderly.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury.Drug Management in the Elderly IBD Patient.Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment The safety of non-biological treatments in Ulcerative Colitis.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.Maintenance therapy options for ulcerative colitis.Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis.European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.MMX® technology and its applications in gastrointestinal diseases.Mesalazine-induced multi-organ hypersensitivity.Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants.Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly.

P2860

Q26768270-7E8B21F3-8362-43EE-B167-B39619D06447 Q26865546-272C0535-75CC-4EE3-9754-88232AD4D683 Q30251570-79D22CA7-7722-4DEE-A7BA-2165A95ACFE1 Q34273329-818DBBE8-54D9-4ED2-8BCE-3590ED31A662 Q35061210-8E159FE7-49E8-4578-8DAC-5C84E0E9FD51 Q36144377-64AE63B1-3F5D-498D-8361-B20F18898F90 Q36172156-6A87E903-531F-465E-B525-9715ABB127CC Q37219195-680A0F60-BA1D-41FA-910F-E04341E79188 Q37290309-8DB1CFDA-F9AE-4E73-8471-0232B615833F Q37528584-93602D51-8F4A-4A27-B469-E66D70A96DCF Q37553057-0027EF27-6B32-4AA7-8DA6-B7E2FD62F4B2 Q37662503-18AF38BE-7C7D-4973-A230-D0EA10C07693 Q37727232-6AC38B4C-9A8D-42EE-9992-7743678F224E Q37743485-9B50CB0C-BC21-42DF-8643-1D26657EEA49 Q37762154-C49C3A21-33E4-4996-92F1-E4F4CD19E623 Q37789000-8FACBDFA-2FA1-45B4-95FC-536C5655A5FC Q37827164-A625695A-1069-42A8-956F-D903AFA92227 Q37862584-3F5E1A8A-63EE-4F35-BD35-7DA08FA5B8EA Q37892884-D2D5E366-6E50-4444-9A13-7F4041C30CBF Q38050885-5590DE13-696C-47E4-9711-467C004D60E5 Q38056892-A9595F4F-0426-4E9E-97DF-DB15A8BCAAAF Q38122069-4778814B-254E-4CC8-A45A-C357BB41D8A0 Q38171926-DB156292-0397-45B8-AC31-25FB65ACF6FE Q38176953-A661A473-1CCA-4551-BF98-0C6972FA7D5A Q38196945-4B7EBF30-7312-4A74-9C08-CAC003DCB270 Q38260985-6B53C8A4-54AB-44FE-B4A4-9D097D382F97 Q38330651-B89B1E60-0FE0-4B69-B986-03706BA6E075 Q38396153-25554912-2EA5-46E1-8675-782DFC3DC2AB Q38609002-30C2B77C-6A49-446B-A4A9-91FC88B1D122 Q38728164-9BA4AEBC-13C5-41BF-A19B-8C01C103B959 Q38735146-B3825F96-AAC0-4E03-97D8-AE5B77842157 Q38812688-1E6B7BE6-8601-4FA7-A44D-5803BA6D0542 Q38848140-5644332D-1E8C-4BB9-92BC-B5AFC56A272E Q38979887-BF99DE3A-0BE5-40EF-91F0-B79D8D62AAA2 Q38995105-E059D039-5953-4E75-A6D2-0C8D014B6FB8 Q40095211-D71F2480-6BD8-42D4-8399-4C22A0FF8CB6 Q40359623-8DE864DF-9E84-460E-83E4-40A9F76CF76B Q40416887-F105CAC5-6BD2-4A4E-BF17-AADA90A70DEB Q40747451-2BFB7FC9-59CB-4FF5-9A24-7E0B489FF4DD Q41169995-BA130542-6D5D-4BC6-AE1E-46374D226B1E

P2860

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

http://www.wikidata.org/entity/Q36715466

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@ast

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@en

type

label

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@ast

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@en

prefLabel

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@ast

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

@en

P1433

Q36715466-0812B02B-38B7-4196-8235-6E5B99361C91

P1476

Q36715466-B2F1EB04-1CC0-4669-9757-1E54FE828D6F

P2093

Q36715466-1711FC11-6E8A-42AF-A810-C54D8246E9FB

Q36715466-9628A707-80B2-4CE9-B6E1-21E9B8CF38B7

P2860

Q36715466-02FB338E-A738-44A8-9459-E075BC0A6449

Q36715466-18F70409-49AB-4EFA-9FE5-CA276C2E3ACF

Q36715466-2D67528E-DB56-42FC-BC25-C8B7AE166626

Q36715466-3D62EC65-65A5-4F34-BC6D-FE1F19540066

Q36715466-4CF40CB4-279F-4958-A697-9CB4E89FFE54

Q36715466-60F5F214-3E63-4582-860F-ED6882869C8B

Q36715466-786D0B6A-73D4-4DBB-8639-4FFA2F73D65D

Q36715466-7A295DFF-9056-4136-94E0-5AF992CA9036

Q36715466-7EC4FCEE-DF19-4D6E-ACAC-B0E6FE845A7B

Q36715466-7ECA4F61-B06C-4AF4-A0CB-B7294CFB63CF

P304

Q36715466-D8CBF74A-C090-4FC8-B70E-20C206941C84

P31

Q36715466-D2E20DF4-D3F6-45C2-A8C9-6F44F8419DA9

P356

Q36715466-59E30F9A-C730-4053-9E7A-1341DDF29222

P433

Q36715466-8CB1C3C7-A2F6-4B20-B54F-0A56D7343938

P478

Q36715466-B6E7B296-C9DB-4A24-BBCA-B328A5344F35

P50

Q36715466-F349997E-00CA-4604-AE1C-EDA4D1C5A504

P577

Q36715466-C6C1B79B-CA0E-42C1-A15C-4CB8EF82A85D

P5875

Q36715466-D0108E55-7955-40C9-8BCB-08B4CDEB1593

P698

Q36715466-3862CF7F-92E4-4273-A63F-ECE8E2594BBC

P921

Q36715466-E6702538-BC8F-4F28-9A12-A9B6B1B3DBE1

P356

P1433

Inflammatory Bowel Diseases

P1476

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review

@en

P2093

José Maté

http://www.w3.org/2001/XMLSchema#string

Yago González-Lama

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic interstitial nephritis due to 5-aminosalicylic acid

Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Review article: monitoring for drug side-effects in inflammatory bowel disease.

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Interstitial nephritis from mesalazine: case report and literature review.

An experiment to determine the active therapeutic moiety of sulphasalazine.

P304

629-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20099

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Javier P Gisbert

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6560246

http://www.w3.org/2001/XMLSchema#string

P698

17243140

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases